Resultados de la búsqueda 121-130 of 3579 for charcoal-activated-oral-route

  1. Salud del adulto - Mayo Clinic

    De Mayo Clinic a tu buzón. Inscríbete gratis y mantente al día en cuanto a avances en las investigaciones, consejos sobre salud, temas médicos de actualidad ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  3. Radiation therapy for prostate cancer - Mayo Clinic

    Radiation therapy, also called radiotherapy, is a type of treatment for prostate cancer. This treatment uses beams or particles of intense energy to kill ...

  4. Cirugía - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. The purposes of this study are to determine whether maternal T cells are activated and expand after in utero intervention, and to determine ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL. ... administration of MV-s- ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...